

1 SUPPLEMENTARY TABLE S1 Cases of proven, probable, and possible IFD reported during
 2 the study

Proven/ probable/ possible ^a	Details	Evidence	POS IV dose, mg	Study day	C _{avg} , ng/mL
Proven	Candidemia Disseminated aspergillosis	Culture Autopsy results	200	3 24	Not calculated ^b
Proven	Pulmonary aspergillosis	Radiographic and histopathologic	300	21	1370
Possible	Pulmonary fungal infection	Radiographic	300	36	1540
Possible	Pulmonary fungal infection	Radiographic	300	7	2230 ^c
Possible	Pulmonary fungal infection	Radiographic	300	7	663
Possible	Pulmonary fungal infection	Radiographic	300	30	2910

3 C_{avg}, average plasma concentration; IFD, invasive fungal disease; IV, intravenous; POS, posaconazole.

4 ^aAccording to the revised European Organization for Research and Treatment of Cancer Mycoses Study
 5 group (¹⁸).

6 ^bStudy medication was stopped on day 5, and C_{avg} was not calculated. Day 3 concentration was 1080
 7 ng/mL.

8 ^cC_{min}, day 6.